ID   SKBR3-AZDRa
AC   CVCL_EI04
DR   cancercelllines; CVCL_EI04
DR   Wikidata; Q54954663
RX   PubMed=26883193;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_132986; Sapitinib (AZD8931).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 12
//
RX   PubMed=26883193; DOI=10.18632/oncotarget.7317; PMCID=PMC4905492;
RA   Creedon H., Gomez-Cuadrado L., Tarnauskaite Z., Balla J., Canel M.,
RA   MacLeod K.G., Serrels B., Fraser C., Unciti-Broceta A., Tracey N.,
RA   Le Bihan T., Klinowska T., Sims A.H., Byron A., Brunton V.G.;
RT   "Identification of novel pathways linking epithelial-to-mesenchymal
RT   transition with resistance to HER2-targeted therapy.";
RL   Oncotarget 7:11539-11552(2016).
//